Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2013. The report details a specific share repurchase transaction executed on August 20, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 634,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,663.00 pence per share; lowest price paid was 1,634.00 pence per share.
- Treasury Holdings (Settled): 510,569,412 shares, representing 9.43% of total issued share capital.
- Treasury Holdings (Including Unsettled): 511,868,412 shares, representing 10.44% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,902,581,116 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 634,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.44% when including unsettled purchases. The filing does not provide comparative data against prior periods for these specific metrics.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (510,569,412 settled) against the company's latest capitalization table.
- Confirm the impact of the 10.44% Treasury holding on total voting rights calculations.
- Check the remaining authorization for share buybacks following this transaction.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F or quarterly reports for those metrics.